Pulnovo Medical Announces Results of the PADN-HF-PH Trial at ESC Congress 2026, Simultaneously Published in The New England Journal of Medicine (NEJM), September 3, 2026

Pulnovo Medical‘s PADN-HF-PH trial results were presented at European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, and published simultaneously in a New England Journal of Medicine article. The multicenter, randomized trial enrolled 264 patients with pulmonary hypertension associated with left heart disease (pulmonary hypertension associated with left heart disease (PH-LHD), World Health Organisation […]

Pulnovo Medical Announces Results of the PADN-HF-PH Trial at ESC Congress 2026, Simultaneously Published in The New England Journal of Medicine (NEJM), September 3, 2026 Read Post »

A familiar drug in unfamiliar territory: Will we manage to repurpose SGLT2 inhibitors in pulmonary arterial hypertension?, Journal of Heart and Lung Transplant, September 3, 2026

The September issue of Journal of Heart and Lung Transplant presents new data pointing to sodium-glucose cotransporter 2 (SGLT2) inhibitors — drugs like dapagliflozin and empagliflozin, originally developed for diabetes — as a potential novel avenue for treating pulmonary arterial hypertension. Initially valued for their effect on kidney glucose reabsorption, sodium-glucose cotransporter 2 (SGLT2) inhibitors

A familiar drug in unfamiliar territory: Will we manage to repurpose SGLT2 inhibitors in pulmonary arterial hypertension?, Journal of Heart and Lung Transplant, September 3, 2026 Read Post »

Tenax Therapeutics announces results from phase 3 LEVEL trial of TNX-103 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, PH-HFpEF, August 10, 2026

Tenax Therapeutics, Inc. announced today the topline results of its Phase 3 LEVEL trial, which evaluated TNX-103 (oral levosimendan) in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), Group 2 of the World Health Organisation (WHO) pulmonary hypertension classification. The trial did not meet its primary endpoint — improvement in

Tenax Therapeutics announces results from phase 3 LEVEL trial of TNX-103 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, PH-HFpEF, August 10, 2026 Read Post »

Live Webinar on Early Referral for Lung Transplantation: Recognizing the Right Time, CHEST, June 2, 2026, recording now available

A live, case-based webinar held on June 2, 2026 looked at when and how patients with advanced pulmonary disease should be referred for lung transplant evaluation. The expert faculty walked through evidence-based referral criteria, disease-specific considerations, and complex scenarios — including interstitial lung disease, pulmonary arterial hypertension, and critically ill patients in the Intensive Care

Live Webinar on Early Referral for Lung Transplantation: Recognizing the Right Time, CHEST, June 2, 2026, recording now available Read Post »

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification, Clinical and Translational Science, July 31, 2026

For 30 years, pulmonary arterial hypertension (World Health Organisation, WHO, Group 1 pulmonary hypertension) treatment relied on three vasodilator-based pathways: endothelin receptor antagonists (bosentan, ambrisentan, macitentan), the nitric oxide/cGMP pathway (sildenafil, tadalafil, riociguat), and prostacyclin pathway agents (treprostinil, epoprostenol, selexipag, etc.). These improve symptoms and slow progression but don’t modify the underlying vascular disease, and

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification, Clinical and Translational Science, July 31, 2026 Read Post »

How Do Sleep Difficulties Interact With Anxiety, Depression and Health-Related Quality of Life in Pulmonary Hypertension? – Clinical Respiratory Journal, August 2026

A cross-sectional study surveyed 111 adults with pulmonary hypertension (see table below for different forms), predominantly UK-based, White, and female, to examine sleep problems and their psychological/quality-of-life impact. The design and procedure of the study were developed in association with the UK Pulmonary Hypertension Association, PHA UK, and medical experts in pulmonary hypertension. Key findings:

How Do Sleep Difficulties Interact With Anxiety, Depression and Health-Related Quality of Life in Pulmonary Hypertension? – Clinical Respiratory Journal, August 2026 Read Post »

Phase 2 trial on new investigational treatment for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) completes enrolment, Pulmonary Hypertension News, June 15, 2026

Pulmonary Hypertension associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) is classified as Group 2 pulmonary hypertension by the World Health Organization (WHO). It is a type of heart failure in which the heart still pumps normally but becomes too stiff to fill properly with blood between heartbeats. This can cause pressure to build

Phase 2 trial on new investigational treatment for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) completes enrolment, Pulmonary Hypertension News, June 15, 2026 Read Post »

Inhaled Therapies for Pulmonary Hypertension: Where We Are and What’s Next, Live PHA webinar on July 23, 2026 at 2 pm EDT

Pulmonary hypertension treatments continue to evolve and one very promising advancing treatment option is inhaled therapy which delivers medication directly to the lungs. The webinar speakers will discuss the current landscape and future of inhaled therapies in pulmonary hypertension, including:• Currently approved inhaled therapies.• Key differences between inhaled treatment options and the conditions they manage,

Inhaled Therapies for Pulmonary Hypertension: Where We Are and What’s Next, Live PHA webinar on July 23, 2026 at 2 pm EDT Read Post »

Tenax Therapeutics reports progress on an investigational drug for World Health Organisation Group 2 pulmonary hypertension, BioSpace, May 12, 2026

Tenax Therapeutics has reported good progress on their Phase 3 LEVEL study investigating TNX-103, a therapy for PH-HFpEF – pulmonary hypertension associated with heart failure with preserved ejection fraction, Group 2 of the World Health Organisation, WHO, classification. Topline data expected in the third quarter of 2026, and enrolment is also advancing in LEVEL-2, a

Tenax Therapeutics reports progress on an investigational drug for World Health Organisation Group 2 pulmonary hypertension, BioSpace, May 12, 2026 Read Post »

Monthly roundup of content shared on the Pulmonary Hypertension Knowledge Sharing Platform – April 2026

Welcome to our April roundup of the most relevant and interesting content shared on this platform. April 2026 has been a particularly rich month, with significant news on the diagnostics, clinical trials and treatment front alongside important research on quality of life, patient preferences information, economic burden. There is also a selection of patient resources

Monthly roundup of content shared on the Pulmonary Hypertension Knowledge Sharing Platform – April 2026 Read Post »

Pulnovo Medical and Medtronic Join Forces to Advance Pulmonary Artery Denervation for Pulmonary Hypertension, Pulse 2.0, April 25, 2026

Pulnovo Medical, a Shanghai-based company developing therapies for pulmonary hypertension and heart failure, has raised $100 million in a strategic financing round led by Medtronic, which has also entered into a separate commercial agreement with the company exploring future commercialisation opportunities. Pulnovo’s flagship product is the Pulmonary Artery Denervation (PADN) System, a minimally invasive device

Pulnovo Medical and Medtronic Join Forces to Advance Pulmonary Artery Denervation for Pulmonary Hypertension, Pulse 2.0, April 25, 2026 Read Post »

Sotatercept for WHO Group 2 pulmonary hypertension sub-group: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study, Circulation, March 29, 2026

The Phase 2 CADENCE randomised controlled trial tested sotatercept in patients with combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction (CpcPH-HFpEF) — a serious condition with high mortality and no proven treatments (Group 2 WHO pulmonary hypertension classification). 164 patients received either sotatercept (at one of two doses) or placebo

Sotatercept for WHO Group 2 pulmonary hypertension sub-group: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study, Circulation, March 29, 2026 Read Post »

René Baumgart Foundation Research Prize 2026 – two awards for groundbreaking pulmonary hypertension research

At the 66th Congress of the German Society for Pneumology in Munich, the €5,000 René Baumgart Foundation research prize was awarded to two outstanding researchers working in the field of pulmonary hypertension (full text in German available at this link) English AI translation and summary Dr. Fenja Knöpp (Justus Liebig University, Giessen) was recognised for

René Baumgart Foundation Research Prize 2026 – two awards for groundbreaking pulmonary hypertension research Read Post »

Tenax Therapeutics extends long-term study of oral levosimendan (TNX-103) in pulmonary hypertension with preserved ejection fraction (HFpEF) patients, February 2026

Tenax Therapeutics is conducting a long-term open-label extension study of TNX-103, an oral formulation of levosimendan, in patients with pulmonary hypertension associated with heart failure and preserved Ejection Fraction (HFpEF), Group 2 of the World Health Organisation classification. In its intravenous form TNX-103 is a drug authorized for use in 60 countries for acute decompensated

Tenax Therapeutics extends long-term study of oral levosimendan (TNX-103) in pulmonary hypertension with preserved ejection fraction (HFpEF) patients, February 2026 Read Post »

Winrevair (sotatercept) meets primary endpoint in Phase 2 CADENCE study on patients with a subset of pulmonary hypertension due to left heart disease (PH-LHD), November 18, 2025

Combined post- and precapillary pulmonary hypertension (CpcPH) represents a subset of pulmonary hypertension due to left heart disease (PH-LHD), also known as World Health Organisation Group 2 pulmonary hypertension. There are currently no treatments specifically approved for this condition. The CADENCE met its primary endpoint, showing a statistically significant and clinically meaningful reduction in pulmonary

Winrevair (sotatercept) meets primary endpoint in Phase 2 CADENCE study on patients with a subset of pulmonary hypertension due to left heart disease (PH-LHD), November 18, 2025 Read Post »

TRANSLATE »
Scroll to Top